Trial · NCT03563066
Effect of Benralizumab in Atopic Dermatitis
NCT03563066, Phase 2, Completed, McMaster University; results first posted 2025-08-22
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Benralizumab in Atopic Dermatitis. Trials, record NCT03563066. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03563066
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Benralizumab in Atopic Dermatitis
- NCT number
- NCT03563066
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 20 participants, actual
- Lead sponsor
- McMaster University
- Conditions
Dermatitis, Atopic, Dermatitis, Eczema, Skin Diseases, Skin Diseases, Genetic, Genetic Diseases, Inborn, Skin Diseases, Eczematous, Hypersensitivity, Hypersensitivity, Immediate, Immune System Diseases
- Interventions
- Benralizumab, Placebo Control
- First posted
- 2018-06-20
- Last updated
- 2025-08-22
- Results first posted
- 2025-08-22
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Allergen-induced Eosinophils in the Skin | Day 65, 24 hours post-intradermal allergen challenge | The primary objective is to evaluate the effect of benralizumab on the allergen-induced number of eosinophils in the skin assessed by histological examination compared to placebo. Intradermal saline challenge will be used as a control. |
| Secondary | Allergen-induced Late Phase Cutaneous Response | Day 65, at 24 hours post-intradermal allergen challenge | To evaluate the effect of Benralizumab on the allergen-induced late phase cutaneous response by measuring the skin wheal compared to placebo. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Allergen-induced Eosinophils in the Skin | Day 65, 24 hours post-intradermal allergen challenge | Full analysis set | cells/mm2 | MEAN |
| SECONDARY | Allergen-induced Late Phase Cutaneous Response | Day 65, at 24 hours post-intradermal allergen challenge | Full analysis set | millimeters | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Allergen-induced Eosinophils in the Skin | Benralizumab | 11.95 | Standard Deviation 28.51 | cells/mm2 | |
| Number of Allergen-induced Eosinophils in the Skin | Placebo Control | 71.15 | Standard Deviation 130.1 | cells/mm2 | |
| Allergen-induced Late Phase Cutaneous Response | Benralizumab | 18.89 | Standard Deviation 6.33 | millimeters | |
| Allergen-induced Late Phase Cutaneous Response | Placebo Control | 26.57 | Standard Deviation 12.07 | millimeters |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Benralizumab | 9 | |
| Overall Study | STARTED | Placebo Control | 11 | |
| Overall Study | COMPLETED | Benralizumab | 9 | |
| Overall Study | COMPLETED | Placebo Control | 11 | |
| Overall Study | NOT COMPLETED | Benralizumab | 0 | |
| Overall Study | NOT COMPLETED | Placebo Control | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Benralizumab | 0 | 9 |
| Total, all-cause mortality | Placebo Control | 0 | 11 |
| Total, other adverse events | Benralizumab | 0 | 9 |
| Total, other adverse events | Placebo Control | 0 | 11 |
| Total, serious adverse events | Benralizumab | 0 | 9 |
| Total, serious adverse events | Placebo Control | 0 | 11 |
Source ClinicalTrials.gov
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Benralizumab vs Placebo Control: deaths from any cause | Trial comparisons |
| Benralizumab vs Placebo Control: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03563066
GET https://conductscience.org/api/trials/v1/NCT03563066/registered